NASDAQ:ALXN
Delisted
Alexion Pharmaceuticals Stock News
$182.50
+0 (+0%)
At Close: May 27, 2022
Alexion's Ultomiris Shows Compelling, Durable Efficacy In Rare Muscle Weakness Disorder
07:29am, Friday, 16'th Jul 2021
Alexion Pharmaceuticals Inc (NASDAQ: ALXN) announced topline results from a Phase 3 study evaluating Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG). The study met
Why Alexion Pharmaceuticals (ALXN) is a Top Momentum Stock for the Long-Term
10:49am, Thursday, 15'th Jul 2021
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here is Why Growth Investors Should Buy Alexion (ALXN) Now
01:53pm, Wednesday, 14'th Jul 2021
Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.
AstraZeneca (AZN) Gets Clearance in UK for Alexion Acquisition
10:51am, Wednesday, 14'th Jul 2021
AstraZeneca (AZN) obtains UK Competition and Markets Authority's permission for the impending acquisition of Alexion. The deal is expected to close on Jul 21, 2021.
AstraZeneca gets final go-ahead for £27.5bn Alexion acquisition
02:47am, Wednesday, 14'th Jul 2021
AstraZeneca PLC's (LON:AZN) expects to complete its £27.5bn acquisition of rare disease specialist Alexion Pharmaceuticals Inc next week after getting the go-ahead from UK authorities. The UK Compe
British watchdog clears AstraZeneca's $39 billion buyout of Alexion
02:26am, Wednesday, 14'th Jul 2021
Britain's competition regulator said on Wednesday it has cleared AstraZeneca's $39 billion buyout of U.S.-based Alexion after it decided not to initiate a broader probe into the deal following its ini
7 Low Price-to-Book Stocks Worth Buying in July
10:06am, Monday, 12'th Jul 2021
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
3 of the Fastest-Growing Dividend Stocks on the Planet
06:35am, Saturday, 10'th Jul 2021
These stocks offer the best of both worlds: rapid sales growth and a market-topping dividend yield.
AstraZeneca (AZN) Gets EC's Clearance for Alexion Acquisition
11:16am, Tuesday, 06'th Jul 2021
AstraZeneca (AZN) obtains European Commission's permission for the acquisition of Alexion. The deal is expected to close in the third quarter of 2021.
AstraZeneca receives EU clearance for £27.5bn Alexion acquisition
03:15am, Tuesday, 06'th Jul 2021
AstraZeneca PLC (LON:AZN) announced it has received EU approval for the US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc., expected to complete in the third quarter. The pharma giant has
ALXN or GMAB: Which Is the Better Value Stock Right Now?
12:47pm, Monday, 05'th Jul 2021
ALXN vs. GMAB: Which Stock Is the Better Value Option?
Apellis Pharmaceuticals Goes After Alexion Blood Disorder Drugs
05:54pm, Thursday, 10'th Jun 2021
Investors seem to think that a drug from fledgling biotech Apellis Pharmaceuticals ( APLS , Financial) can go head-to-head with established treatments backed by a competitor 10 times its size.
BOSTON--(BUSINESS WIRE)--Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)
AstraZeneca to appoint new chief financial officer when Alexion acquisition completes
02:56am, Friday, 04'th Jun 2021
AstraZeneca PLC (LON:AZN) announced it has appointed Aradhana Sarin as an executive director and chief financial officer, effective from 1 August. The appointment is conditional on the success of the
AstraZeneca names Alexion's Sarin as new finance chief
02:08am, Friday, 04'th Jun 2021
Drugmaker AstraZeneca Plc said on Friday it had appointed Alexion's Aradhana Sarin as its new chief financial officer to succeed Marc Dunoyer who would be taking up a new role within the company.
